Teysuno: Withdrawal of the application to change the marketing authorisation

tegafur / gimeracil / oteracil


On 6 January 2015, Nordic Group BV officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a change to the indication for Teysuno. The change concerned extending the use of Teysuno to treat advanced gastric cancer in combination with platinum-based cancer medicines other than cisplatin.

  • List item

    Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Teysuno (tegafur/gimeracil/oteracil) (PDF/239.86 KB)

    First published: 23/01/2015
    Last updated: 23/01/2015

  • Key facts

    Product number
    Date of issue of market authorisation valid throughout the European Union (if applicable)
    International non-proprietary name (INN) or common name
    • tegafur
    • gimeracil
    • oteracil
    Active substance
    • tegafur
    • gimeracil
    • oteracil
    Date of withdrawal
    Company making the application
    Nordic Group B.V.
    Withdrawal type

    All documents

    Related information on withdrawals

    The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

    How useful was this page?

    Add your rating